By James Schulze
This article discusses changes in the mass tort market and how qualified volume at scale is essential to building a client base and driving economics that make sense. It also highlights the need for intake efficiency, using AI and other tools to ensure intake capacity is not a limiting factor.
Mass tort marketing continues to change in 2026, but one fundamental part of the business has not changed: lead volume is critical. Law firms need legitimate claimants who meet the requirements of a particular litigation, but they also need enough potential cases entering the pipeline to build a meaningful mass tort portfolio.
According to the Bureau of Justice Statistics, approximately 95% to 99% of mass tort and motor vehicle accident (MVA) cases settle out of court rather than going to a full trial verdict. That basic dynamic is not new. Settlement rates were similarly high a decade ago. What has changed is the scale of the market. Case volumes and litigation costs have increased, major settlements can involve enormous amounts of money, and technology is allowing firms to process potential claimants more efficiently.
For mass tort law firms and lead buyers, success increasingly requires a combination of lead volume, lead quality, and efficient intake. For law firms, The Leads Warehouse has a variety of lead types for current mass torts and MVA. Lead offerings include real-time leads, call transfers, and full intake leads (i.e., signed retainers) (read our blog, “Mass Tort Leads Explained – Signed Cases, Long-Form Leads, And Co-Reg Real-Time Data”).
Mass tort remains a volume business
The quality of mass tort leads matters, but focusing on quality without discussing volume misses an important part of mass tort economics. Very few cases ultimately reach a jury verdict. Most are resolved through settlements, coordinated settlement programs, dismissals, or other resolutions.
Law firms need a large pipeline of potential claimants. Not every mass tort lead will answer the phone. Not every person contacted will complete intake. Some consumers will lack documentation, fail final qualification, or decide not to proceed. Attrition is a normal part of the process.
That means a firm needs enough legitimate opportunities entering the top of the funnel to produce the desired number of signed cases at the bottom. The objective should not be maximum volume at the expense of quality, but it also should not be to have such restrictive qualification that potentially valuable claimants never enter the process. The goal is qualified volume at scale.
Settlement rates are similar, but the market has grown
The percentage of mass tort and MVA cases settling rather than reaching trial has remained relatively consistent over the past decade. What has changed underneath that percentage is the number of cases, the cost of litigation, and the potential financial value of major settlements.
The rise of large jury awards and so-called nuclear verdicts has also increased the potential risk associated with taking certain cases to trial. Meanwhile, large multidistrict litigation can involve tens of thousands of individual claimants moving through the legal system.
For mass tort lead buyers, that scale is important. Large-scale litigation requires large-scale claimant acquisition. A firm participating in a major mass tort cannot build a substantial portfolio by finding a handful of perfect claimants. It needs a consistent flow of potential cases and an intake operation capable of determining which should move forward.
Lead quality is still important
Volume does not mean every lead has equal value. Mass tort qualification can be complicated, and the criteria can vary dramatically between litigations. A claimant may need to have used a particular product or medication, experienced a specific injury, received a qualifying diagnosis, or been exposed during a certain period. Medical records, product usage, dates, and other documentation may also be required.
Reasonable screening helps remove consumers who clearly do not meet basic requirements before significant intake resources are spent on them. But there is a balance. If screening is too loose, intake teams can become overwhelmed. If it becomes too restrictive, firms may sacrifice the volume needed to build a meaningful case inventory. Quality and volume should work together rather than compete with one another.
A key to understanding volume is how mass tort leads are generated. At The Leads Warehouse, we offer:
- Co-registration (co-reg) real-time mass tort leads
- Long-form real-time mass tort leads
- Mass tort call transfers
- Mass tort full intake leads
Lead quality, qualification, cost, and available volume exist on a sliding scale. A co-reg mass tort lead can be compliant and good quality, but it is a high-volume mass tort lead. A law firm needs to purchase these at scale and have a solid outbound approach with fronters and closers. At the other end of the spectrum, a mass tort full intake lead is a very high-quality lead with exceptional close rates, but this comes at a higher cost and at the expense of volume. A real-time mass tort lead from a long-form, standalone page is a middle-ground mass tort lead; it has lower volume than co-reg leads but lower price and higher volume than full intake leads.
Buying a mass tort lead that does not match a law firm’s sales process can make a great lead ineffective and seemingly a “bad” lead.
AI is changing mass tort intake
Artificial intelligence is becoming increasingly important to mass tort intake (read our blog, “Why AI Is Increasing The Value Of High-Quality Mass Tort Leads”). A single potential claimant can generate questionnaires, medical records, diagnoses, product histories, dates, supporting documents, and other information that historically required substantial manual review.
AI can help summarize medical records, organize claimant information, identify missing documentation, assist with initial screening, and prioritize potential cases for additional human review. This does not eliminate the need for experienced intake personnel or attorneys. It can, however, allow those people to spend less time organizing information and more time evaluating potential cases.
That has an important effect on mass tort or MVA lead generation. If technology allows a firm to efficiently evaluate more potential claimants, the firm can potentially process more lead volume without increasing staffing at the same rate. Better technology does not necessarily mean buying fewer leads. It may make buying and processing more leads economically practical.
Intake capacity is becoming a marketing issue
Generating thousands of mass tort leads provides little benefit if a firm’s intake operation cannot effectively process them. So, intake capacity is becoming part of the marketing equation.
Law firms need systems for contacting prospects, applying qualification criteria, collecting additional information, obtaining documentation, following up, and moving qualified claimants toward signed retainers. CRM systems, automated communications, digital forms, call center technology, and AI-assisted review can all help increase that capacity.
Improving intake efficiency can ultimately allow a firm to increase the number of leads it purchases and processes. For firms participating in large mass tort campaigns, that can translate directly into a larger inventory of signed cases.
Full intake mass tort leads have become exceptionally popular as it allows a law firm to focus on cases rather than the sales and intake process.
The entire funnel matters
Cost per lead (CPL) and lead volume are both important considerations, but neither should be evaluated alone. A typical acquisition funnel might look like this:
- Leads
- Contacts
- Qualified claimants
- Completed intakes
- Signed retainers
- Viable cases
- Settlements
Every stage reduces the original pool, which is another reason volume matters. A lower-cost lead source may require more leads, contact attempts, and screening but still produce an attractive cost per signed case. A more heavily qualified lead source may cost substantially more while requiring less intake work.
Both models can work. What matters is understanding the economics through the entire funnel rather than judging a campaign exclusively by CPL or qualification rate.
MVA leads follow similar economics
Motor vehicle accident leads are different from mass tort leads, but there are similarities. Approximately 95% to 99% of MVA and mass tort cases resolve without a full trial verdict, making a strong pipeline of legitimate potential clients important in both markets.
The intake process is different. MVA leads typically involve a specific accident that has already occurred, making speed-to-lead particularly important. Mass tort qualification may require deeper investigation into product use, exposure, diagnosis, medical history, and documentation.
The broader principle is similar: volume creates opportunities, qualification identifies stronger opportunities, and intake converts those opportunities into signed cases.
Mass tort marketing is about scale and efficiency
Mass tort firms do not need to choose between volume and quality. They need both. The major change in 2026 is the increasing ability to manage that volume efficiently. Better data can identify which lead sources are producing cases. Better intake can reduce lost opportunities. AI can help firms process larger amounts of claimant information without abandoning reasonable qualification standards.
For law firms and mass tort lead buyers, that changes the conversation. The objective is no longer simply finding the cheapest leads or restricting campaigns to a small number of highly screened prospects. The opportunity is building an operation capable of acquiring qualified mass tort leads at scale and efficiently turning that volume into signed cases. Are you ready to talk about how you can grow your mass tort sales pipeline?
About the author
James Schulze is the President and CEO of The Leads Warehouse, a marketing data company with over 20 years of experience in bringing lead generation solutions to companies selling into the home, automotive, financial, insurance, health and life, and legal sectors. He works directly with clients to optimize conversion strategies and ROI across multiple verticals.
Connect with James Schulze on LinkedIn:
https://www.linkedin.com/in/james-l-schulze
Read additional market analysis and commentary from James Schulze on Substack:
https://jameslschulze.substack.com
If you would like more information on how you can grow your mass tort sales, give The Leads Warehouse a call at 1-800-884-8371 or visit our website at https://theleadswarehouse.com.
